SPOTLIGHT: New Sativex trial planned

GW Pharmaceuticals is hoping to add to its trove of positive data on Sativex as a therapy for pain associated with multiple sclerosis with a second Phase III trial now underway. Data is expected in about a year. Report

Suggested Articles

German scientists are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate.

The 100 largest companies trading on the London Stock Exchange have boosted the percentage of women on their boards, but has life sciences kept pace?

In this week's EuroBiotech Report, Bicycle lands Genentech collaboration, GSK inks COVOD-19 adjuvant deal and Grifols buys antibiotic assets.